Spots Global Cancer Trial Database for resistant
Every month we try and update this database with for resistant cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Picoplatin as Second-Line Therapy for Patients With Small Cell Lung Cancer | NCT00116610 | Small Cell Lung... | picoplatin | 18 Years - | Poniard Pharmaceuticals | |
| Platinum-Resistant, Recurrent Epithelial Ovarian Cancer | NCT00484666 | Ovarian Cancer | 18 Years - | Carilion Clinic | ||
| A Phase 2 Trial of SCO-101 in Combination With FOLFIRI for Patients With Metastatic Colorectal Cancer (mCRC) With Acquired Resistance to FOLFIRI | NCT04247256 | Metastatic Colo... | FOLFIRI Protoco... SCO-101 | 18 Years - | Scandion Oncology A/S | |
| INTERVAL - Intense Exercise Trial for Men With Metastatic Castrate-Resistant Prostate Cancer | NCT04507698 | Prostate Cancer | Intensive Exerc... | 18 Years - | Guy's and St Thomas' NHS Foundation Trust | |
| Managed Access Program to Provide Alpelisib for Patients With HR+ Advanced or Metastatic Breast Cancer | NCT03706573 | HR+ Advanced or... | alpelisib | 18 Years - | Novartis | |
| Masitinib in Patients With Gastro-Intestinal Stromal Tumour Resistant to Imatinib | NCT01506336 | Gastro Intestin... | masitinib sunitinib | 18 Years - | AB Science | |
| Masitinib in Patients With Gastro-Intestinal Stromal Tumour Resistant to Imatinib | NCT01506336 | Gastro Intestin... | masitinib sunitinib | 18 Years - | AB Science | |
| Efficacy of Pazopanib in Gastrointestinal Stromal Tumors (GIST) | NCT01323400 | GIST | Pazopanib Best supportive... | 18 Years - 90 Years | Centre Leon Berard | |
| Nilotinib and LDE225 in the Treatment of Chronic or Accelerated Phase Myeloid Leukemia in Patients Who Developed Resistance to Prior Therapy | NCT01456676 | Philadelphia Ch... | Nilotinib + LDE... | 18 Years - | Novartis | |
| Managed Access Program to Provide Alpelisib for Patients With HR+ Advanced or Metastatic Breast Cancer | NCT03706573 | HR+ Advanced or... | alpelisib | 18 Years - | Novartis | |
| INTERVAL - Intense Exercise Trial for Men With Metastatic Castrate-Resistant Prostate Cancer | NCT04507698 | Prostate Cancer | Intensive Exerc... | 18 Years - | Guy's and St Thomas' NHS Foundation Trust | |
| Study of TBX-3400 in Subjects With Solid Malignant Tumors Resistant or Refractory to Standard Therapies | NCT04640246 | Cancer Tumor, Solid Refractory Canc... | TBX-3400 | 18 Years - | Taiga Biotechnologies, Inc. | |
| Study of TBX-3400 in Subjects With Solid Malignant Tumors Resistant or Refractory to Standard Therapies | NCT04640246 | Cancer Tumor, Solid Refractory Canc... | TBX-3400 | 18 Years - | Taiga Biotechnologies, Inc. | |
| A Phase I Study of Bi-Weekly rBBX-01 in Patients With Solid Tumors | NCT00869388 | Solid Tumors | rBBX-01 | 18 Years - | Washington University School of Medicine | |
| 131I-Labeled MIBG for Refractory Neuroblastoma: A Compassionate Use Protocol | NCT01370330 | Neuroblastoma | Metaiodobenzylg... | 1 Year - | University of California, San Francisco | |
| Active Symptom Control Alone Or In Combination With Oral Topotecan In Patients With Relapsed Resistant Small Cell Lung Cancer | NCT00276276 | Lung Cancer, Sm... | topotecan | 18 Years - | GlaxoSmithKline | |
| Study of Imatinib Mesylate in Combination With Hydroxyurea Versus Hydroxyurea Alone as an Oral Therapy in Patients With Temozolomide Resistant Progressive Glioblastoma | NCT00154375 | Glioblastoma Mu... Astrocytoma | Imatinib mesyla... Hydroxyurea | 18 Years - 70 Years | Novartis | |
| High-Dose 131I-MIBG Therapy Combined With Vincristine and Five Days of Irinotecan for Resistant/Relapsed Neuroblastoma | NCT01313936 | Neuroblastoma | Metaiodobenzylg... | 1 Year - 30 Years | University of California, San Francisco | |
| High-Dose 131I-MIBG Therapy Combined With Vincristine and Five Days of Irinotecan for Resistant/Relapsed Neuroblastoma | NCT01313936 | Neuroblastoma | Metaiodobenzylg... | 1 Year - 30 Years | University of California, San Francisco | |
| A Phase II Study of 131I- Metaiodobenzylguanidine (MIBG) for Treatment of Metastatic or Unresectable Pheochromocytoma and Related Tumors | NCT01413503 | Pheochromocytom... Paraganglioma | 131I-MIBG | 4 Years - | University of California, San Francisco | |
| A Phase Ib Study of ISF35 in Combination With Chemotherapy (FCR) in Subjects With Relapsed, Refractory, and/or 17p- CLL | NCT00772486 | Chronic Lymphoc... | ISF35 | 18 Years - | Memgen, Inc. | |
| Study of Apatinib in Patients With Differentiated Thyroid Cancer | NCT02731352 | Thyroid Cancer | Apatinib Apatinib | 18 Years - | Peking Union Medical College Hospital | |
| A Study of CG-806 in Patients With Relapsed or Refractory AML or Higher-Risk MDS | NCT04477291 | Acute Myeloid L... Myelodysplastic... | CG-806 | 18 Years - | Aptose Biosciences Inc. | |
| A Phase Ib Study of ISF35 in Combination With Chemotherapy (FCR) in Subjects With Relapsed, Refractory, and/or 17p- CLL | NCT00772486 | Chronic Lymphoc... | ISF35 | 18 Years - | Memgen, Inc. | |
| Study of Imatinib Mesylate in Combination With Hydroxyurea Versus Hydroxyurea Alone as an Oral Therapy in Patients With Temozolomide Resistant Progressive Glioblastoma | NCT00154375 | Glioblastoma Mu... Astrocytoma | Imatinib mesyla... Hydroxyurea | 18 Years - 70 Years | Novartis | |
| Study of TBX-3400 in Patients With Stage III and IV Melanoma Resistant or Refractory to Immune Checkpoint Inhibitors | NCT03385486 | Stage III Melan... Stage IV Melano... | TBX-3400 | 18 Years - | Taiga Biotechnologies, Inc. | |
| A Phase II Study of 131I- Metaiodobenzylguanidine (MIBG) for Treatment of Metastatic or Unresectable Pheochromocytoma and Related Tumors | NCT01413503 | Pheochromocytom... Paraganglioma | 131I-MIBG | 4 Years - | University of California, San Francisco |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
